Bristol Myers Squibb Co. (BMY)
66.82
-1.27
(-1.87%)
USD |
NYSE |
Sep 04, 16:00
66.82
0.00 (0.00%)
Pre-Market: 20:00
Bristol Myers Squibb Research and Development Expense (Quarterly) : 2.316B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.316B |
| March 31, 2026 | 2.238B |
| December 31, 2025 | 2.561B |
| September 30, 2025 | 2.433B |
| June 30, 2025 | 2.262B |
| March 31, 2025 | 2.236B |
| December 31, 2024 | 2.788B |
| September 30, 2024 | 2.353B |
| June 30, 2024 | 2.295B |
| March 31, 2024 | 2.694B |
| December 31, 2023 | 2.476B |
| September 30, 2023 | 2.178B |
| June 30, 2023 | 2.258B |
| March 31, 2023 | 2.301B |
| December 31, 2022 | 2.51B |
| September 30, 2022 | 2.36B |
| June 30, 2022 | 2.321B |
| March 31, 2022 | 2.22B |
| December 31, 2021 | 2.607B |
| September 30, 2021 | 3.25B |
| June 30, 2021 | 3.271B |
| March 31, 2021 | 2.224B |
| December 31, 2020 | 2.79B |
| September 30, 2020 | 2.496B |
| June 30, 2020 | 2.483B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.316B |
| December 31, 2019 | 1.988B |
| September 30, 2019 | 1.362B |
| June 30, 2019 | 1.309B |
| March 31, 2019 | 1.30B |
| December 31, 2018 | 1.358B |
| September 30, 2018 | 1.262B |
| June 30, 2018 | 2.416B |
| March 31, 2018 | 1.23B |
| December 31, 2017 | 1.411B |
| September 30, 2017 | 1.479B |
| June 30, 2017 | 1.088B |
| March 31, 2017 | 1.231B |
| December 31, 2016 | 1.214B |
| September 30, 2016 | 1.138B |
| June 30, 2016 | 1.127B |
| March 31, 2016 | 1.136B |
| December 31, 2015 | 1.175B |
| September 30, 2015 | 1.132B |
| June 30, 2015 | 1.856B |
| March 31, 2015 | 1.016B |
| December 31, 2014 | 1.041B |
| September 30, 2014 | 983.00M |
| June 30, 2014 | 958.00M |
| March 31, 2014 | 946.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Pfizer Inc. | 2.746B |
| AstraZeneca PLC | 3.456B |